SAB Biotherapeutics, Inc. Common Stock (SABS) is a publicly traded Healthcare sector company. As of May 21, 2026, SABS trades at $3.58 with a market cap of $272.21M and a P/E ratio of 16.77. SABS moved +3.66% today. Year to date, SABS is -1.60%; over the trailing twelve months it is +99.71%. Its 52-week range spans $1.00 to $6.60. Analyst consensus is strong buy with an average price target of $12.17. Rallies surfaces SABS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
SAB Biotherapeutics Starts GMP Manufacturing, Expands Plasma Network 30% in Q1: In its Q1 2026 earnings call SAB Biotherapeutics announced initiation of GMP manufacturing for its lead hyperimmune therapeutic and a 30% expansion of its plasma collection network to support pipeline scalability. Management also spotlighted progress across two preclinical antibody programs targeting emerging viral pathogens.
| Metric | Value |
|---|---|
| Price | $3.58 |
| Market Cap | $272.21M |
| P/E Ratio | 16.77 |
| EPS | $0.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.60 |
| 52-Week Low | $1.00 |
| Volume | 1.58K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $13.27M |
| Gross Margin | 0.00% |
7 analysts cover SABS: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.17.